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pneumoniaeAbstract This study evaluated the incidence, serotype distribution, and
antimicrobial susceptibility of invasive pneumococcal disease (IPD) in Saudi Arabian
children. This multicenter, prospective, clinical surveillance study included children
under 5 years of age, residents of one of the seven study health areas, who were
brought to a study hospital with suspicion of IPD. Bacterial isolates from sterile site
samples, collected less than 24 h after hospital visit/admission, were identified, ser-
otyped, and tested for antibiotic susceptibility. Between June 2007 and January
2009, 631 episodes of suspected IPD were recorded, and 623 were included in the
analysis. One child (0.2%) had previously received one dose of a pneumococcal
vaccine. Forty-seven episodes were positive for Streptococcus pneumoniae and
three for Haemophilus influenzae. The incidence of confirmed IPD cases was esti-
mated to be 2.5–21.6 per 100,000 children (<5 years). Among the 46 S. pneumoniae
isolates serotyped and tested for antibiotic susceptibility, the most common
serotypes were 5 and 23F (20% each), 6B (17%), and 1 and 14 (11% each). Sixty-
three percent of isolates were multidrug-resistant. Vaccination of Saudi Arabian
children with expanded-coverage conjugate pneumococcal vaccines containing
serotypes 1 and 5 could have a substantial impact to prevent IPD in this population.
 2015 Ministry of Health, Saudi Arabia, Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).
96 Y. Almazrou et al.1. Introduction
Invasive pneumococcal disease (IPD) caused by
Streptococcus pneumoniae is a major cause of
morbidity and mortality worldwide, especially in
young children and elderly people; its most severe
manifestations include bacteremia, septicemia,
bacteremic pneumonia, and meningitis [1,2]. A
previous study conducted in 1999–2003 in Saudi
Arabia has estimated an average annual IPD inci-
dence of 17.4/100,000 children younger than
5 years of age, a case fatality rate of 12.2%, and
an almost fourfold higher incidence of IPD in the
1st year of life compared with the next 4 years
[3]. That study may underestimate the true IPD
burden in Saudi Arabia since only microbiologically
confirmed IPD cases (meningitis or bacteremia)
were included in the analyses [3]. Additionally, as
the study focused only on hospitalized children,
outpatient bacteremia was not assessed and blood
cultures from pneumonia were frequently not per-
formed [3].
Currently, more than 90 pneumococcal sero-
types have been identified based on differences
in capsular polysaccharides. The serotype distribu-
tion varies somewhat between different geograph-
ical regions, especially regarding the relative
prominence of serotypes 1 and 5 [4,5]. In a study
conducted in 2000–2004 on 350 isolates collected
from children in different regions of Saudi Arabia,
the most common invasive S. pneumoniae serotype
was 14, followed by serotypes 23F, 6B, and 19F.
These serotypes were shown to account for 80%
of the invasive pneumococcal isolates resistant to
widely used antibiotics (penicillin, erythromycin,
and cefotaxime); in Saudi Arabia, different antibi-
otics are prescribed against these pathogens as
there are no national guidelines [6].
Other studies conducted in Saudi Arabia have
shown a high and increasing prevalence of
multidrug-resistant S. pneumoniae isolates
[6–14]. The emergence of antimicrobial resistance
among pneumococcal isolates is a major health
problem in many other countries and is mainly
due to the extensive and inappropriate use of
antibiotics [15].
Since certain serotypes occur with different fre-
quencies due to outbreaks, temporal variability in
serotype distribution can be observed. The existing
data need to be updated and the relative value of
expanded serotype conjugate vaccines needs to
be understood. Moreover, the true IPD incidence
rate in Saudi Arabia remains unclear, as does
the geographical representativeness of previous
studies. The current clinical study assesses theincidence per health area (except Riyadh and
Jeddah) of IPD in Saudi Arabian children younger
than 5 years of age, along with the distribution of
pneumococcal serotypes and antibiotic susceptibil-
ity of S. pneumoniae isolates, in both inpatient and
outpatient populations that had not yet benefited
from the introduction of pneumococcal conjugate
vaccination. Additionally, this study attempted to
provide information on other bacterial pathogens
causing invasive disease in Saudi Arabian children,
such as Haemophilus influenzae and Neisseria
meningitidis and to describe antimicrobial drug
resistance patterns of these pathogens in Saudi
Arabian children suspected of having IPD.
2. Materials and methods
2.1. Study design and participants
This multicenter, prospective, national, clinical
surveillance study was conducted in 12 hospitals
located in seven health areas (Al Gassim, Al Baha,
Al Jouf, Al Madeenah, Al Qateef, Riyadh City, and
Jeddah City), to represent the epidemiology and
disease burden across Saudi Arabia. The selected
study hospitals from Riyadh and Jeddah do not
accurately represent the catchment area for these
two cities because of other private and public
healthcare centers not included in this study; for
this reason the two areas were excluded from the
incidence calculation. The recruitment period
was longer than 1 year to take seasonal variations
into account (June 2007–January 2009). The study
was conducted according to Good Clinical Practice,
the Declaration of Helsinki, and the local rules and
regulations of the country. The study protocol and
the consent form were reviewed and approved by
the Ministry of Health or the National Independent
Ethics Committee. Before enrollment, informed
consent was obtained from the parents/guardians
of each study participant.
This study included children younger than
5 years of age suspected of having IPD, who were
residents of the study areas and were brought to
one of the study hospitals. Suspected IPD cases
were identified by the local physicians according
to their individual clinical judgment. IPD was sus-
pected if at least one of the following pulmonary
symptoms was present: dyspnea, chest discomfort,
pleuritic pain, chest splinting, cough productive of
purulent or blood-tinged sputum, tachypnea, or
tachycardia. Other symptoms included fever (axil-
lary temperature >37.5 C), elevated white blood
cells (>15,000), suspicion of meningitis, or systemic
complains. At each study hospital, attempts were
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regarding the value of blood culturing when IPD
was suspected. IPD was confirmed if S. pneumoniae
was isolated from a normally sterile site, regard-
less of the clinical symptoms.
Children were eligible if sterile site samples
(blood, cerebrospinal fluid, pleural fluid, or syn-
ovial fluid) had been collected by the local clinician
less than 24 h after the hospital visit/admission. If
a child was enrolled more than once for the same
S. pneumoniae infection, only the first episode
was retained for analysis. A case was considered
a new S. pneumoniae infection if symptoms
occurred at least 21 days after the first episode
with the same pathogen or if the serotype was
different. As serotyping was not performed at the
hospital, all children meeting the inclusion criteria
were enrolled.
2.2. Study procedures
All children younger than 5 years of age with
clinical symptoms of IPD were anonymously
recorded in a screening logbook. Two different
logbooks were used: one for the outpatients and
emergency room patients (hereafter referred to as
outpatient group) and another for the hospitalized
patients who had at least one overnight stay in
hospital before diagnosis (inpatient group).
For sterile site samples collected less than 24 h
after hospital visit/admission, parents/guardians
were asked to sign the informed consent, and
inclusion criteria were checked to enroll the chil-
dren in the study. Clinical and demographic charac-
teristics, including risk factors (chronic pulmonary
disease or asthma; immunosuppression or immun-
odeficiency; HIV positive or AIDS; malignancy,
leukemia, or Hodgkin’s disease; splenectomy or
asplenia; sickle cell anemia; renal dysfunction;
chronic cardiovascular disease or failure; cere-
brospinal fluid leak; malnutrition; burns; or other),
pneumococcal conjugate vaccination history,
general symptoms, and antibiotic pretreatment
were recorded in a case report form (CRF) for each
enrolled child.
Samples were cultured and bacterial isolates
identified at local laboratories. These bacterial
isolates were shipped together with the CRF to
the central laboratory at King Saud University for
re-identification, serotyping, and antibiotic
susceptibility testing. Samples were preferably col-
lected before antibiotic administration, but if the
child had received antibiotic at any point before
taking the sterile site sample, this was stated in
the CRF together with the type of antibiotic taken.(The laboratory procedures are available in the
Supplementary material.)
2.3. Statistical analysis
The estimation of the expected annual incidence of
IPD was based on incidences reported in hospital-
based studies in Europe (20–40/100,000 children
<5 years of age) [5,16]. Based on these estimates,
a minimum of 37–75 episodes were expected in
this study.
Calculations for the incidence rates of invasive
disease due to S. pneumoniae, H. influenzae, or
N. meningitidis were derived from the total num-
ber of new episodes of confirmed invasive disease
caused by each pathogen, including those episodes
for which no informed consent was obtained.
This was a descriptive study and no statistical
comparisons were performed. Continuous variables
were described with the number of nonmissing
observations, mean, standard deviation, median,
minimum and maximum, and number of missing
observations. Categorical variables were described
with frequency tables and absolute numbers and
percentages for each level were given. All confi-
dence intervals were two-sided 95% confidence
intervals and were calculated from Proc StatXact.
All statistical analyses were performed using SAS
version 9.2.
3. Results
3.1. Demographic and baseline
characteristics of enrolled individuals
Between June 2007 and January 2009, 1030 epi-
sodes were screened, 631 of which were recorded
as suspected IPD. Six hundred and twenty-three
episodes in 622 children were analyzed: 621 chil-
dren who experienced a single infection and one
child who had two infections.
Forty-five episodes (7.2%) were reported in
infants <1 month of age, 290 episodes (46.5%) in
infants aged 1 month–1 year, and the remaining
288 episodes (46.2%) in children 1–5 years of
age (Table 1). Of the 623 episodes, 61.8%
(385/623) were reported in the inpatient group
and 38.2% (238/623) in the outpatient group.
The mean age of the children was 15.0
± 14.2 months; 45.3% (282/623) of episodes
occurred in girls. In this study, one child (0.2%)
had received pneumococcal vaccination prior to
enrollment. Baseline characteristics of the
enrolled children were similar to those of the
screened children.
Table 1 Demographic characteristics and clinical information regarding children suspected of having IPD who were
included in the study.
Inpatientsa Outpatientsb Total
Nc 385 238 623
Age (mo) (mean ± SD) 15.9 ± 14.8 13.4 ± 12.9 15.0 ± 14.2
Age category (mo) nd (%)
<1 28 (7.3) 17 (7.1) 45 (7.2)
1–11 172 (44.7) 118 (49.6) 290 (46.5)
12–59 185 (48.1) 103 (43.3) 288 (46.2)
Gender n (%)
Male 215 (55.8) 126 (52.9) 341 (54.7)
Pneumococcal vaccination n (%)
Yes 1 (0.3) 0 (0.0) 1 (0.2)
Antibiotic pretreatment n (%)
Yes 40 (10.4) 64 (26.9) 104 (16.7)
Unknown 16 (4.2) 25 (10.5) 41 (6.6)
Antibiotic taken in hospital prior to sample collection n (%)
Yes 2 (0.5) 8 (3.4) 10 (1.6)
Hospitalization after diagnosis
n (%) 385 (100) 236 (99.2) 621 (99.7)
Duration (d) (mean ± SD) 6.0 ± 7.4 7.6 ± 8.1 6.6 ± 7.7
IPD = invasive pneumococcal disease; SD = standard deviation.
a Hospitalized patients with at least one overnight stay in hospital before diagnosis.
b Outpatients and patients brought to emergency room.
c Total number of episodes.
d Number (percentage) of episodes in the specified category.
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Pretreatment with antibiotics within the past 48 h
before the hospital visit/admission was reported
in 104/623 (16.7%) episodes (Table 1). Overall,
621/623 (99.7%) episodes were followed by hospi-
talization after diagnosis, and the mean duration
of hospitalization was 6.6 days. The most frequent
presentation leading to suspicion of IPD was pneu-
monia, reported in 387/623 (62.1%) episodes
(Table 2). Pneumonia was confirmed only by using
an X-ray in 97.9% (379/387) as opposed to cases
confirmed by detection of pleural effusion/
empyema in 2.1% (8/387) of these episodes.
Risk factors for IPD were present in 149/623
(23.9%) episodes. The most frequently reported
condition was chronic pulmonary disease/asthma,
present in 56/149 (37.6%) episodes, followed by
chronic cardiovascular disease in 25/149 (16.8%)
episodes, and sickle cell anemia in 18/149 (12.1%)
episodes.
At discharge, 598/623 (96.0%) episodes had
recovered. However, seven children (1.1%) died
during this study; one episode (0.2%) was followed
by sequelae, and two episodes (0.3%) resulted in
neurological problems due to IPD.3.3. Identification and incidence of
pathogens
Only 50/623 (8.0%) blood samples tested positive
for bacteria and were sent to the central labora-
tory for further testing (Table 3). Cerebrospinal
fluid was collected for 125/623 (20.1%) episodes,
out of which only eight samples (6.4%) tested pos-
itive for bacteria and were sent to the central lab-
oratory. Two blood samples and one cerebrospinal
fluid sample were lost and thus could not be further
tested for antibiotic susceptibility and serotype
determination. Out of the 50 episodes confirmed
for invasive disease, 47 were positive for S. pneu-
moniae and three for H. influenzae, with no cases
of co-infection. No samples were positive for
N. meningitidis. Of the 47 episodes positive for
S. pneumoniae, 22 were reported in infants
younger than 1 year of age and 25 in children
1–5 years of age. Overall, the presence of
S. pneumoniae was confirmed in 7.5% (47/623) of
suspected IPD episodes.
Of the 48 samples tested by the central labora-
tory, 46 were positive for S. pneumoniae and were
serotyped (26 in the inpatient group; 20 in the
outpatient group). The most frequently isolated
Table 2 Clinical presentation of children suspected of having IPD.
Clinical presentation at the visit Inpatientsa
Nc=385
Outpatientsb
N = 238
Total
N = 623
nd (%) n (%) n (%)
Bacteremia without focus Yes 99 (25.7) 36 (15.1) 135 (21.7)
Meningitis Yes 29 (7.5) 16 (6.7) 45 (7.2)
Pneumonia Yes 216 (56.1) 171 (71.8) 387 (62.1)
X-ray confirmed pneumonia Yes 212 (98.1) 167 (97.7) 379 (97.9)
Missing/NA 169 () 67 () 236 ()
Pleural effusion/empyema Yes 4 (1.9) 4 (2.3) 8 (2.1)
Missing/NA 169 () 67 () 236 ()
Otitis media Yes 16 (4.2) 10 (4.2) 26 (4.2)
Bronchitis Yes 8 (2.1) 0 (0.0) 8 (1.3)
Epiglottitis No 385 (100) 238 (100) 623 (100)
Peritonitis No 385 (100) 238 (100) 623 (100)
Pericarditis Yes 0 (0.0) 2 (0.8) 2 (0.3)
Cellulitis Yes 1 (0.3) 3 (1.3) 4 (0.6)
Septic arthritis Yes 1 (0.3) 1 (0.4) 2 (0.3)
Osteomylitis Yes 1 (0.3) 0 (0.0) 1 (0.2)
Abscess (not skin) Yes 2 (0.5) 0 (0.0) 2 (0.3)
Other Yes 43 (11.2) 17 (7.1) 60 (9.6)
IPD = invasive pneumococcal disease; NA = not applicable.
a Hospitalized patients with at least one overnight stay in hospital before diagnosis.
b Outpatients and patients brought to emergency room.
c Total number of episodes.
d Number (percentage) of episodes in the specified category.
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were each identified in 9/46 episodes (20%), fol-
lowed by 6B in 8/46 episodes (17%), and 1 and
14, each in 5/46 episodes (11%) (Table 4). Serotype
23F was more frequently identified in the outpa-
tient group than in the inpatient group (6/20 versus
3/26). Serotypes 1 and 5 seemed to be more fre-
quently identified in the inpatient group (4/26
and 6/26) than in the outpatient group (1/20 and
3/20). Of note, serotype 19A was only identified
in one sample (2.2%) in this study.
The point estimates for incidence of confirmed
IPD cases, caused by S. pneumoniae, varied
between 2.5/100,000 and 21.6/100,000 children
<5 years of age in the different health areas
included (Table 5).
Two of the three confirmed H. influenzae epi-
sodes were identified in infants <1 year of age. Both
H. influenzae positive samples sent to the central
laboratory were nontypeable (data not shown).
The number of H. influenzae positive samples was
too small to calculate incidences by region.
3.4. Antibiotic susceptibility
Among the S. pneumoniae isolates tested for
antibiotic susceptibility, 78% (36/46) were mul-
tidrug resistant (Table 6). The majority of isolateshad low susceptibility to penicillin: 30% (14/46)
showed intermediate resistance and 39% (18/46)
were resistant. Additionally, 30% of isolates were
resistant to chloramphenicol, while 43% showed
intermediate resistance and 54% were resistant to
trimethoprim–sulfamethoxazole. All isolates were
sensitive to ceftriaxone.
The two tested H. influenzae isolates were sen-
sitive to all antibiotics except cefuroxime, for
which they showed intermediate resistance (data
not shown).
4. Discussion
In this surveillance study, S. pneumoniae was con-
firmed in 7.5% of Saudi Arabian children <5 years of
age suspected of having IPD who were brought to
one of the study hospitals. Although the confidence
intervals overlapped, the point estimates of the
incidence of IPD varied between 2.5/100,000 and
9.6/100,000 in children younger than 5 years of
age in the different health areas included in the
study, with the exception of 21.6 in Al-Baha City.
Interestingly, apart from this one exception, the
incidence in these areas was lower compared with
17.4/100,000 children reported by a previous study
conducted in children younger than 5 years of age
admitted to hospitals in Riyadh and Jeddah [3].
Table 3 Bacterial etiology determined at local and central laboratories by sterile site sample.
Laboratory Sample origin Characteristics Categories Inpatientsa
Nc = 385
Outpatientsb
N = 238
Total
N = 623
nd (%) n (%) n (%)
Local hospital Blood Sample collected Yes 385 (100) 238 (100) 623 (100)
Bacterial species identified Streptoccoccus pneumoniae 27 (7.0) 20 (8.4) 47 (7.6)
Haemophilus influenzae 3 (0.8) 0 (0.0) 3 (0.5)
Other 354 (92.2) 218 (91.6) 572 (92.0)
Missing/NA 1 (–) 0 (–) 1 (–)
Cerebro-spinal fluid Sample collected Yes 80 (20.8) 45 (18.9) 125 (20.1)
Bacterial species identified S. pneumoniae 4 (5.1) 4 (8.9) 8 (6.5)
Other 75 (94.9) 41 (91.1) 116 (93.5)
Missing/NA 306 (–) 193 (–) 499 (–)
Pleural fluid Sample collected Yes 1 (0.3) 1 (0.4) 2 (0.3)
Bacterial species identified Other 1 (100) 1 (100) 2 (100)
Missing/NA 384 (–) 237 (–) 621 (–)
Otherc normally sterile site Sample collected Yes 4 (1.0) 13 (5.5) 17 (2.7)
Bacterial species identified Other 4 (100) 13 (100) 17 (100)
Missing/NA 381 (–) 225 (–) 606 (–)
Central laboratory Blood Sample received Yes 28 (7.3) 20 (8.4) 48 (7.7)
Bacterial species identified S. pneumoniae 26 (92.9) 20 (100) 46 (95.8)
H. influenzae 2 (7.1) 0 (0.0) 2 (4.2)
Missing/NA 357 (–) 218 (–) 575 (–)
Cerebro-spinal fluid Sample received Yes 1 (0.3) 0 (0.0) 1 (0.2)
Bacterial species identified S. pneumoniae 1 (100) 0 (–) 1 (100)
Missing/NA 384 (–) 238 (–) 622 (–)
NA = not applicable.
a Hospitalized patients with at least one overnight stay in hospital before diagnosis.
b Outpatients and patients brought to emergency room.
c Total number of episodes. Bacterial species except S. pneumoniae, H. influenzae and Neisseria meningitides.
d Number (percentage) of episodes in the specified category.
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Table 4 Serotype distribution of Streptococcus pneumoniae isolates causing invasive pneumococcal disease in children
<5 years of age.
Pneumococcal serotype Inpatientsa
Nc = 26
Outpatientsb
N = 20
Total
N = 46
nd % n % n %
1 4 15.4 1 5.0 5 10.9
4 1 3.8 1 5.0 2 4.3
5 6 23.1 3 15.0 9 19.6
6B 4 15.4 4 20.0 8 17.4
9V 0 0.0 1 5.0 1 2.2
11A 1 3.8 0 0.0 1 2.2
14 3 11.5 2 10.0 5 10.9
15 2 7.7 0 0.0 2 4.3
19A 1 3.8 0 0.0 1 2.2
19F 1 3.8 2 10.0 3 6.5
23F 3 11.5 6 30.0 9 19.6
a Hospitalized patients with at least one overnight stay in hospital before diagnosis.
b Outpatients and patients brought to emergency room.
c Total number of episodes.
d Number (percentage) of episodes in the specified category.
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than 5 years old occurring in the less than 1 year
age group (335/623; 53.6%) in the present study
was similar to that observed in 1999–2003
(39/82; 47.6%) in Saudi Arabian children [3].
Nonetheless, the true burden of IPD, and thus the
potential impact of a pneumococcal conjugate vac-
cine (PCV) is likely to be substantially greater than
these numbers would suggest. A randomized clini-
cal trial demonstrated that at least three times
more clinically suspected IPD cases can be pre-
vented by pneumococcal vaccination than microbi-
ologically confirmed cases [17].
Pneumococcal serotypes 5, 23F, 6B, 1, and 14
were the most frequently identified serotypes in
Saudi Arabian children with IPD in this study. ThisTable 5 Incidence of confirmed invasive disease episodes by
Health area Bacterial species
Buraidah Haemophilus influenzae
Streptococcus pneumoniae
Al Baha City S. pneumoniae
Sikaka Province S. pneumoniae
Al Madeenah City S. pneumoniae
Al Qateef Province S. pneumoniae
Riyadh City S. pneumoniae
Jeddah City H. influenzae
S. pneumoniae
The catchment area for Riyadh City and Jeddah City were not ava
CI = confidence interval.
a Number of confirmed episodes of invasive pneumococcal diseas
b Population of children <5 years of age in the given health areaserotype distribution differs from that observed
in 2000–2004, when serotype 14 was the most
common serotype in Saudi Arabian children,
followed by 23F, 6B, and 19F [6]. The serotype
distribution in the present study, which enrolled
children with clinical symptoms is, however,
similar to that identified from isolates collected
as routine surveillance in 2005–2010, when
serotype 23F was the most common, followed by
6B, 5 and 1 [18]. In 2010, serotype 23F was the
most prevalent in Saudi Arabia, followed by 19F,
19A, 6B, 7F, 5 and 1 [18]. Previously, serotypes 5
and 1 were infrequently identified (each in 1.4%
of the isolates) [6], while in the present study,
these serotypes were identified in 20% and 11% of
the isolates, respectively. The differences inhealth area and pathogen for children <5 years of age.
na Nb Incidence per 100,000 (95% CI)
2 49,461 4.04 (0.49–14.61)
4 49,461 8.09 (2.20–20.71)
4 18,549 21.56 (5.88–55.21)
1 17,685 5.65 (0.14–31.50)
9 94,246 9.55 (4.37–18.13)
1 39,613 2.52 (0.06–14.07)
26 – –
1 – –
2 – –
ilable.
e.
during 2007.
Table 6 Antibiotic susceptibility of Streptococcus pneumoniae isolates from children <5 years of age.
Inpatientsa
Nc = 26
Outpatientsb
N = 20
Total
N = 46
Characteristics Categories nd % n % n %
Antibiotics susceptibility
test performed
Yes 26 100 20 100 46 100
Multidrug resistance Yes 16 61.5 13 65.0 29 63.0
No 10 38.5 7 35.0 17 37.0
Penicillin Intermediate 10 38.5 4 20.0 14 30.4
Resistant 10 38.5 8 40.0 18 39.1
Azithromycin Intermediate 2 7.7 0 0.0 2 4.3
Resistant 10 38.5 6 30.0 16 34.8
Amoxicillin/clavulanate Intermediate 0 0.0 3 15.0 3 6.5
Trimethoprim/sulfamethoxazole Intermediate 9 34.6 11 55.0 20 43.5
Resistant 16 61.5 9 45.0 25 54.3
Chloramphenicol Resistant 6 23.1 8 40.0 14 30.4
Cefaclor Intermediate 1 3.8 1 5.0 2 4.3
Resistant 15 57.7 9 45.0 24 52.2
Cefuroxime Intermediate 3 11.5 2 10.0 5 10.9
Resistant 13 50.0 8 40.0 21 45.7
a Hospitalized patients with at least one overnight stay in hospital before diagnosis.
b Outpatients and patients brought to emergency room.
c Total number of episodes.
d Number (percentage) of episodes in the specified category.
102 Y. Almazrou et al.serotype distribution between the two studies are
in line with previous observations [19,20] that the
seasonal peaks in IPD caused by serotypes 1 and 5
might occur following cyclical patterns every 3–
4 years. In the present study, serotype 19A, which
shows reduced susceptibility to antibiotics, was
infrequently identified (1 single case representing
2.2% of the isolates), in line with previous findings
in Saudi Arabia (2000–2004) [6]. However, in the
post-PCV7 era, in 2009–2010, serotype 19A was
considered to be responsible for 20% of IPD cases
in the Western region of Saudi Arabia, possibly
due to local antibiotic pretreatment practices,
which could affect the serotypes isolated by blood
culture [18]. The burden of IPD due to serotype 19A
has been increasing in some countries around the
world, especially in European and North American
countries and in Australia [21,22]. Finally, serotype
3 was not identified in young Saudi Arabian children
with IPD, confirming the results of other studies
showing that this serotype is not a common cause
of IPD in this age group [22]. Although the afore-
mentioned study [18] reported antibiotic resis-
tance and serotype distribution, our study
additionally calculated incidence based on the
samples collected from patients with clinical
symptoms.
Local epidemiological data are useful to evalu-
ate the impact of pneumococcal vaccines on IPD.In the present study, the potential pneumococcal
vaccine serotype coverage rates among Saudi
Arabian children younger than 5 years of age were
estimated to be 61% (28/46 isolates) for PCV7,
and to be significantly higher for PHiD-CV (91%;
42/46 isolates) and PCV13 (93%; 43/46 isolates).
However, these figures do not take into account
potential cross-protection; evidence of cross-
protection against serotype 6A has long existed
for PCV7, and PHiD-CV is similarly immunogenic
against that serotype; in addition, there is emerg-
ing evidence of cross-protection against serotype
19A for PHiD-CV [23].
In line with previous reports in Saudi Arabia, 63%
of the S. pneumoniae isolates in this study showed
multidrug resistance. The frequent occurrence of
multidrug-resistant isolates may be partially
explained by the high and inappropriate use of
antibiotics in Saudi Arabia [6–14]. Of note, the
proportion of isolates with decreased susceptibility
to penicillin was higher in this study than in a pre-
vious study conducted in 2000–2004 (70% vs. 54%),
using the same susceptibility criteria [6]. The
proportion of fully resistant isolates was higher in
our study compared with previous observations
(39% vs. 12%), while that of isolates showing inter-
mediate resistance to penicillin was lower (30% vs.
42%). It is important to note that we utilized the
2005 National Committee for Clinical Laboratory
Invasive pneumococcal disease in children 103Standards susceptibility criteria in order to facili-
tate comparisons with the previous studies; apply-
ing the cutoffs associated with more recent Clinical
and Laboratory Standards Institute 2014 criteria,
which only affect interpretation of the penicillin
results, would tend to decrease somewhat the pro-
portion of nonmeningitis isolates considered fully
resistant.
Nontypeable H. influenzae (NTHi) was identified
in two episodes of suspected IPD. The 11-valent PCV
using NTHi protein D as carrier, which was the pre-
cursor of PHiD-CV, has shown some efficacy against
acute otitis media caused by NTHi [24]. However,
additional studies are needed to determine
whether PHiD-CV itself has such efficacy and
whether efficacy would extend to invasive disease
caused by NTHi. In this study, N. meningitidis was
not responsible for any invasive disease episodes.
Limitations of this study include low culture pos-
itivity rate, a previously reported problem that
could be mitigated by using molecular detection
techniques [25]. False-negative cultures may result
from previous antibiotic use, insufficient sample
volume, or inadequate storage and transportation
conditions [26]. The reported antibiotic use was
high in enrolled children, especially outpatients,
and possibly underestimated, since no urine
antimicrobial tests were performed.
In conclusion, this multicenter prospective clin-
ical surveillance study conducted between June
2007 and January 2009 showed that S. pneumoniae
was the most commonly identified pathogen in
Saudi Arabian children younger than 5 years of
age with confirmed invasive disease. The most
common pneumococcal serotypes were 5, 23F,
6B, 1, and 14, with antibiotic resistance being a
major issue. Although this study was conducted
largely in the pre-PCV era, these data remain
relevant as vaccine-type IPD can continue to
circulate and potentially cause disease even after
several years of universal mass vaccination PCV
programs [23]. Therefore, vaccination of Saudi
Arabian children with expanded coverage conju-
gate pneumococcal vaccines, especially PHiD-CV
and PCV13, would have a substantial impact to
prevent IPD in this population.Conflicts of interest
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